Revolution Medicines, Inc(NASDAQ:RVMD) 
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gyne...
Website: http://www.revmed.com
Founded: 2014
Full Time Employees: 117
CEO: Mark A. Goldsmith
Sector: Healthcare
Industry: Biotechnology
Share this website to your friends
The information provided in this report is taken from www.sec.gov. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.
Day
Week
Month
Date 2025-04-04
P
O 31.92
H 33.02
L 30.97
C 31.32
V 2,376,753
10EMA 31.32
20EMA 31.32
60EMA 31.32
120EMA 31.32
250EMA 31.32